Wandong Medical Reports: Full-line Products Obtain the MDR Certification, Facilitating Its Entry to the European Market

Recently, Wandong’s seven major series of products obtained the MDR certificate, following the completion of the first MDR certification for superconducting magnetic resonance.

So far, Wandong’s full range of X-ray, CT and MRI products have been completed the switching from CE MDD to CE MDR.

High standards define high reliability
CE certification, as a “visa” for products to enter the European market, is a mandatory requirement for product access in the EU market. The Medical Device (MDR) Regulation (EU) 2017/745 was issued in May 2017, compared with the MDD directive, the MDR regulation has stricter and more comprehensive requirements for medical devices, and the pre-market certification review is more difficult and the certification cycle is longer, and all those changes has raised the threshold for certification.

Wandong always follows a high level of standard, and the full range of X-ray, CT and MRI products have been completed certification of CE MDR.

Established in China, Impacting the World

Wandong Medical, as a professional manufacturer in the medical imaging industry, always adheres to technology innovation, continuously improves its quality management, and is committed to launching high-quality, high-performance, reliable products for customers all over the world.

The MDR certification acts as a catalyst for Wandong Medical to expand its coverage in the international market, accelerate the process of globalization, and contribute Chinese solutions to the health of people around the world.

Beijing Wandong Medical Technology Co.,Ltd has dedicated itself to the R&D, manufacture, sales and service of medical imaging equipment for nearly 70 years. In addition to a wide sales and service network all over China, our export destination covers more than 70 countries. With strict production and quality management, our MRI systems and major X-ray equipment are ISO/CE/FDA cleared. Over 8500 units of equipment are manufactured annually.

The company philosophy, “Precision and Vision”, is our motivation to strive for advancement and innovation.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”